Rx-360 Summary of ICH Q3D Draft
ICH posted the 79-page, step 2b version of ICHQ3D, Guideline for Elemental Impurities on its website on 5 August 2013.
Consultation comments are due to both FDA and EMA in December 2013. The scope of the guideline includes chemically synthesised drugs, proteins and polypeptides made using cell culture expression systems and resulting conjugated proteins/polypeptides. Elemental impurities in drug product may come from a variety of sources including those added during chemical synthesis, the presence of elemental impurities in raw materials, or those that result from contact with processing equipment.
This guideline identifies elemental impurities that may have potential health/toxicology impact, establishes Permitted Daily Exposure (PDE) of those impurities and addresses controls necessary to maintain the impurities below the recommended PDE. The document includes seven sections (not including the Introduction and Scope) and four appendices as follows:
• Safety Assessment of Potential Elemental Impurities (pages 2-4)
• Element Classification (page 4)
• Assessment and Control of Elemental impurities (pages 5-13)
• Speciation (page 14)
• Analytical Procedures (page 14)
• Life-Cycle Management of the Control Strategy for Elemental Impurities
(page 14)
• Recommendations for Submission of Elemental Impurities Control Strategy (page 14)
• Appendix 1: Method for Establishing Exposure Limits (pages 20–22)
• Appendix 2: Established PDEs for Elemental Impurities (pages 23–25)
• Appendix 3: Individual Safety Assessments (pages 25–69)
• Appendix 4: Illustrative Example — Calculation Options for Converting PDEs to Concentrations (pages 69–79).
To view or download the ICH Q3D Document, click here
To view or download the Rx-360 Summary, click here
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance